title: Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases.
abstract: BACKGROUND
  The Intergroup 0116 study showed a survival benefit with adjuvant chemoradiotherapy (CRT) for resected gastric cancer. We report our experience using conformal radiotherapy (RT).
  
  
  METHODS
  Eighty-two patients with resected gastric or gastroesophageal junction (GEJ) adenocarcinoma, Stage IB to IV (M0), were treated with 45 Gy in 25 fractions using a 5-field conformal technique. Chemotherapy was in accordance with the Intergroup 0116 study, or infusional 5-fluorouracil and cisplatin in a phase I/II trial.
  
  
  RESULTS
  Mean age was 56.4 years. Median follow-up was 22.8 months. Grade 3 or greater acute toxicity (National Cancer Institute Common Terminology Criteria of Adverse Events, version 3.0) was noted in 57% of patients (upper gastrointestinal tract 34%, hematologic 33%). One patient died of neutropenic sepsis. Radiation Therapy Oncology Group Grade 3 late toxicity included esophageal strictures (3 patients) and small bowel obstruction (1 patient). Full course CRT was completed by 67% of patients. Of 26 patients who relapsed, 20 died. Site of first relapse was available on 23 patients: 8 locoregional and distant, 4 locoregional alone, 11 distant alone. Overall and relapse-free survival were 69% and 54% at 3 years.
  
  
  CONCLUSIONS
  Adjuvant CRT for gastric cancer, even with conformal RT, is associated with significant toxicity. Survival was comparable to that reported in the Intergroup 0116 study.
authors.affiliation: Department of Radiation Oncology, The Princess Margaret Hospital, Toronto, ON, Canada.
authors.forename: Zahra
authors.initials: Z
authors.lastname: Kassam
authors.forename: Gina
authors.initials: G
authors.lastname: Lockwood
authors.forename: Catherine
authors.initials: C
authors.lastname: O'brien
authors.forename: James
authors.initials: J
authors.lastname: Brierley
authors.forename: Carol
authors.initials: C
authors.lastname: Swallow
authors.forename: Amit
authors.initials: A
authors.lastname: Oza
authors.forename: Lillian
authors.initials: L
authors.lastname: Siu
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Knox
authors.forename: Rebecca
authors.initials: R
authors.lastname: Wong
authors.forename: Bernard
authors.initials: B
authors.lastname: Cummings
authors.forename: John
authors.initials: J
authors.lastname: Kim
authors.forename: Malcolm
authors.initials: M
authors.lastname: Moore
authors.forename: Jolie
authors.initials: J
authors.lastname: Ringash
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D004943:Esophagogastric Junction; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D020266:Radiotherapy, Conformal; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D016019:Survival Analysis
chemical_list: D015251:Epirubicin; D002945:Cisplatin; D005472:Fluorouracil